Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).

Barbanti PieroGabriella EgeoCinzia AuriliaFlorindo d'OnofrioMaria AlbaneseIlaria CettaPaola Di FioreMaurizio ZuccoMassimo FilippiFrancesco BonoClaudia AltamuraStefania ProiettiStefano BonassiFabrizio Vernierinull null

Published in: The journal of headache and pain (2022)

Fremanezumab seems more effective in real-life than in RCTs. Younger age emerges as a potential response predictor.

Keyphrases

high frequency
transcranial magnetic stimulation
cross sectional
risk assessment
human health
climate change
study protocol